Article 4 of breast cancer patients often a result of bone metastasis and bone pain symptoms, but also prone to fractures, in the lumbar spine, thoracic fracture, etc. will be nerve compression caused by lower limb paralysis, urinary incontinence and so on, so to prevent bone metastasis of breast cancer complications arising out of survival for a longer period of breast cancer is a very important task.
Two-phosphate-type drugs can indeed reduce the complications of bone metastases, there are second-generation Aredia and third generations of Zometa, for breast cancer patients, the third-generation drug Zometa than the second generation of Aredia is good? Los Angeles medical research team of Dr. Luo Sen cancer research team that Zometa is indeed better than a good Aredia. Study group is to have a 1130 breast cancer patients with bone metastases, Zometa and Aredia is divided into two groups; Zometa this group is divided into 4 mg and 8 mg dose to make analysis of the use of comparison, the long-term follow-up to analyze the three treatment plans, to see which group is more effective prevention of skeletal complications. The three groups of about 44% of patients do have bone-related complications; the results of the analysis is Zometa to prevent bone-related complications such as fractures, spinal compression effect even better than Aredia, but the size of dose and efficacy of unrelated, but the side effects of low-dose less than high dose.
Concluded that the prevention of bone metastases for the effectiveness of third-generation better than the second generation, but so far such treatment does not extend the lives of patients, but it can reduce complications after bone metastases, which can really improve the quality of life of patients .
No comments:
Post a Comment